биохимия атеросклероза

108Kathryn E. Naus and Cheryl L. Wellington

6.Zilversmit DB: Atherogenesis: A postprandial phenomenon. Circulation 60: 473–485, 1979.

7.Zilversmit DB: Atherogenic nature of triglycerides, postprandial lipemia, and triglyceride-rich remnant lipoproteins. Clin Chem 41: 153–158, 1995.

8.Napoli C, D’Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W: Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. J Clin Invest 100: 2680–2690, 1997.

9.Criqui MH, Golomb BA: Epidemiological aspects of lipid abnormalities. Am J Med 105: 48S–57S, 1998.

10.Criqui MH: Triglycerides and cardiovascular disease. Eur Heart J 19: A36–A39, 1998.

11.Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW: A definition of initial, fatty streak and intermediate lesions of atherosclerosis. Arterioscler Thromb 14: 840–856, 1994.

12.Stary HC: Natural history and histological classification of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20: 1177–1178, 2000.

13.Solberg LA, Strong JP: Risk factors and atherosclerotic lesions. Arteriosclerosis 3: 187–198, 1983.

14.Kannel WB, Wilson PWF: Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 124: 768–774, 1992.

15.Kannel WB: High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 52: 9B–12B, 1983.

16.Kwiterovich PO: The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82: 13Q–21Q, 1998.

17.Hoeg JM: Lipoproteins and atherogenesis. Endocrinol Metabol Clin 27: 569–584, 1998.

18.Lusis AJ: Atherosclerosis. Nature 407: 233–241, 2000.

19.Meyers CD, Kashyap ML: Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol 19: 366–373, 2004.

20.Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8–15, 1989.

21.Toth PP, Davidson MH: Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr Opin Cardiol 19: 374–379, 2004.

22.Ross R, Glomset JA: The pathogenesis of atherosclerosis. N Engl J Med 295: 369–377, 1976.

23.Gaziano JM, Hennekens CH, O’Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. Circulation 96: 2520–2525, 1997.

24.Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and their risk of myocardial infarction. N Engl J Med 325: 373–381, 1991.

25.Stein O, Stein Y: Atheroprotective mechanisms of HDL. Atheroscler 144: 285–301, 1999.

26.Eisenberg S: High density lipoprotein metabolism. J Lipid Res 25: 1017–1058, 1984.

27.Asztalos BF: High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study. Curr Opin Cardiol 19: 385–391, 2004.

28.Fielding CJ, Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res 36: 211–228, 1995.

29.von Eckardstein A, Assmann G: High density lipoproteins and reverse cholesterol transport: Lessons from mutations. Atherosclerosis 137: S7–S11, 1998.

30.Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R: Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 290: 2292–2300, 2003.

31.Kobayashi J, Okamoto H, Otabe M, Bujo H, Saito Y: Effect of HDL, from Japanese white rabbit administered a new cholesterol ester transfer protein inhibitor JTT-705, on cholesterol ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis 162: 131–135, 2002.

32.Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H: A cholesterol ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406: 203–207, 2000.

33.de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJP: Efficacy and safety of a novel cholesterol ester transfer protein inhibitor, JTT-705, in humans. Circulation 105: 2159–2165, 2002.

34.Ma K, Cilingioroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L: Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci USA 100: 2748–2753, 2002.

35.Jin W, Millar JS, Broedl U, Glick JM, Rader DJ: Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 111: 357–362, 2003.

36.Ishida T, Choi S, Kundu RK, Irata K, Rubin EM, Cooper AD, Quertermous T: Endothelial lipase is a major determinant of HDL level. J Clin Invest 111: 347–355, 2003.

37.Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH: Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23: 712–719, 2003.

38.Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR: Efflux and atherosclerosis: The clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol 23: 1322–1332, 2003.

39.Phillips MC, Johnson WJ, Rothblat GH: Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta 906: 223–276, 1987.

40.Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC: Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40: 781–796, 1999.

41.Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 518–520, 1996.

42.Krieger M: The “best” of cholesterols, the “worst” of cholesterols: A tale of two receptors. Proc Natl Acad Sci USA 95: 4077–4080, 1998.

110Kathryn E. Naus and Cheryl L. Wellington

43.Landschulz KT, Pathak RK, Rigotti A, Krieger M, Hobbs HH: Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 98: 984–995, 1996.

44.de la Llera-Moya M, Connelly MA, Drazul D, Klein SM, Favari E, Yancey PG, Williams DA, Rothblat GH: Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J Lipid Res 42: 1969–1978, 2001.

45.Yancey PG, de la Llera-Moya M, Swarnaker S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, Rothblat GH: HDL phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor-BI (SR-BI). J Biol Chem 275: 36596–36604, 2000.

46.Ji Y, Jian B, Wang N, Sun Y, de la Llera-Moya M, Phillips MC, Rothblat GH, Swaney JB, Tall AR: Scavenger receptor BI promotes high density lipoproteinmediated cellular cholesterol efflux. J Biol Chem 272: 20982–20985, 1997.

47.Rigotti A, Acton S, Krieger M: The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 270: 16221–16224, 1995.

48.de la Llera-Moya M, Rothblat GH, Connelly MA, Kellner-Weibel G, Sakr SW, Phillips MC, Williams DL: Scavenger receptor BI (SRBI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 40: 575–580, 1999.

49.Jian B, de la Llera-Moya M, Royer L, Rothblat G, Francone O, Swaney JB: Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J Lipid Res 38: 734–744, 1997.

50.Kellner-Weibel G, de la Llera-Moya M, Connelly MA, Stoudt G, Christian AE, Haynes MP, Williams DL, Rothblat GH: Expression of scavenger receptor BI in COS-7 cells alters cholesterol content and distribution. Biochemistry 39: 221–229, 2000.

51.Babitt J, Trigatti B, Rigotti A, Smart EJ, Anderson RGW, Xu S, Krieger M: SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 272: 13242–13249, 1997.

52.Graf GA, Connell PM, van der Westhuyzen DR, Smart EJ: The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J Biol Chem 274: 12043–12048, 1999.

53.Liu T, Krieger M, Kan H-Y, Zannis VI: The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoproteins and SR-BI is required for efficient lipid transport. J Biol Chem 277: 21576–21584, 2002.

54.Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42: 1007–1017, 2001.

55.Dean M, Allikmets R: Complete characterization of the human ABC gene family. J Bioenerg Biomemb 33: 475–479, 2001.

56.Schmitz G, Kaminski WE, Orsó E: ABC transporters in cellular lipid trafficking. Curr Opin Lipidol 11: 493–501, 2000.

57.Brooks-Wilson A, Marcil M, Clee SM, Zhang L, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HOF, Loubser O, Ouellette BFF, Fichter K, Ashbourne Excoffon KJD, Sensen CW, Scherer S, Mott S, Denis M, Martindale D,

Frohlich J, Morgan K, Koop B, Pimstone SN, Kastelein JJP, Genest J Jr, Hayden MR: Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22: 336–345, 1999.

58.Rust S, Rosier M, Funke H, Amoura Z, Piette J-C, Deleuze J-F, Brewer HB Jr, Duverger N, Denèfle P, Assmann G: Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22: 352–355, 1999.

59.Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch-Özcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G: The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22: 347–351, 1999.

60.Hayden MR, Clee SM, Brooks-Wilson A, Genest J Jr, Attie A, Kastelein JJP: Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol 11: 117–122, 2000.

61.Tall AR, Wang N: Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 106: 1263–1270, 2000.

62.Rust S, Walter M, Funke H, von Eckardstein A, Cullen P, Kroes HY, Hordijk R, Geisel J, Kastelein J, Molhuizen HOF, Schreiner M, Mischke A, Hahmann HW, Assmann G: Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat Genet 20: 96–98, 1998.

63.Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J: The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 38: 191–205, 1997.

64.Glomset JA, Norum KR: The metabolic role of lecithin:cholesterol acyltransferase: Perspectives from pathology. Adv Lipid Res 11: 1–65, 1973.

65.Glomset JA: The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 9: 155–167, 1968.

66.Liu B, Krieger M: Highly purified scavenger receptor class B, type I reconstituted into phosphatidylcholine/cholesterol liposomes mediates high affinity HDL binding and selective lipid uptake. J Biol Chem 277: 34125–34135, 2002.

67.Singaraja RR, Bocher V, James ER, Clee SM, Zhang L-H, Leavitt BR, Tan B, Brooks-Wilson A, Kwok A, Bissada N, Yang Y-Z, Liu G, Tafuri SR, Fievet C, Wellington CL, Staels B, Hayden MR: Human ABCA1 BAC transgenic mice show increased HDL-C and ApoA1-dependent efflux stimulated by an internal promoter containing LXREs in intron 1. J Biol Chem 276: 33969–33979, 2001.

68.Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain WJ, Fruchart-Najib J, Neufeld ED, Remaley AT, Brewer HB Jr, SantamarinaoFojo S: ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 108: 303–309, 2001.

69.Singaraja R, Fievet C, Castro G, Jamers ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart J-C, McManus BM, Hayden MR: Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 110: 35–42, 2002.

70.Schmitz G, Langmann T: Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim Biophys Acta, 1735: 1–19.

71.Fitzgerald ML, Moore KJ, Freeman MW: Nuclear hormone receptors and cholesterol trafficking: the orphans fine a new home. J Mol Med 80: 271–281, 2002.

72.Edwards PA, Kast HR, Anisfeld AM: BAREing it all: the adoption of LXR and FXR and their roles in lipid metabolism. J Lipid Res 43: 2–12, 2002.

112Kathryn E. Naus and Cheryl L. Wellington

73.Santamarina-Fojo S, Remaley AT, Neufeld EB, Brewer HB Jr: Regulation and intracellular trafficking of the ABCA1 transporter. J Lipid Res 42: 1339–1345, 2001.

74.Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B: Role of LXRs in control of lipogenesis. Genes Devel 14: 2831–2838, 2000.

75.Costet P, Luo Y, Wang N, Tall AR: Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275: 28240–28245, 2000.

76.Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ: Regulation of absorption and ABC1mediated efflux of cholesterol by RXR heterodimers. Science 289: 1524–1529, 2000.

77.Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA,

Tontonoz P: Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proc Natl Acad Sci USA 97: 12097–12102, 2000.

78.Schwartz K, Lawn RM, Wade DP: ABC1 gene expression and ApoA-1- mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun 274: 794–802, 2000.

79.Bortnick AE, Rothblat GH, Stoudt G, Hoppe KL, Royer LJ, McNeish J, Francone OL: The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J Biol Chem 275: 28634–28640, 2000.

80.Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart J-C, Glineur C, Staels B: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22: 717–726, 2002.

81.Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy P, Edwards PA, Curtiss LK, Evans RM, Tontonoz P: A PPARγ-LXR- ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7: 161–171, 2001.

82.Chinetti G, Fruchart J-C, Staels B: Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol 14: 459–468, 2003.

83.Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD,

Kliewer SA, Hansen BC, Willson TM: A selective peroxisome proliferator-acti- vated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98: 5306–5311, 2001.

84.Akiyama TE, Sakai S, Lambert G, Nichol CJ, Matsusue K, Pimprale S, Lee Y-H,

Ricote M, Glass CK, Brewer HB, Gonzalez FJ: Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biochem 22: 2607–2619, 2002.

85.Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential

inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest 114: 1564–1576, 2004.

86.Gan X, Kaplan R, Menke JG, MacNaul K, Chen Y, Sparrow CP, Zhou G, Wright SD, Cai TQ: Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem 276: 48702–48708, 2001.

87.Baranova I, Vishnyakova T, Bocharov A, Chen Z, Remaley AT, Stonik J, Eggerman TL, Patterson AP: Lipopolysaccharide down regulates both scav-

enger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun 70: 2995–3003, 2002.

88.Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR: Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J Lipid Res 44: 1728–1736, 2003.

89.Panousis CG, Zuckerman SH: Interferon-gamma induces down-regulation of Tangier disease gene (ATP-binding cassette transporter 1) in macrophagederived foam cells. Arterioscler Thromb Vasc Biol 20: 1565–1571, 2000.

90.Panousis CG, Evans GA, Zuckerman SH: TGF-beta increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells: opposing the effects of IFN-gamma. J Lipid Res 42: 856–863, 2001.

91.Wang XQ, Panousis CG, Alfaro ML, Evans GF, Zuckerman SH: Interferon- gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway. Arterioscler Thromb Vasc Biol 290: 891–897, 2002.

92.Huuskonen J, Vishnu M, Pullinger CR, Fielding PE, Fielding CJ: Regulation of ATP-binding cassette transporter A1 transcription by thyroid hormone receptor. Biochemistry 43: 1626–1632, 2004.

93.Wang N, Chen W, Linsel-Nitschke P, Martinez LO, Agerholm-Larsen B, Silver DL, Tall AR: A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 111: 99–107, 2003.

94.Martinez LO, Agerholm-Larsen B, Wang N, Chen W, Tall AR: Phosphorylation of a Pest sequence in ABCA1 promotes calpain degradation and is reversed by apoA-I. J Biol Chem 278: 37368–37374, 2003.

95.Yamauchi Y, Hayashi M, Abe-Dohmae S, Yokoyama S: Apolipoprotein A-I activates protein kinase Cα signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem 48: 47890–47897, 2003.

96.See RH, Caday-Malcolm RA, Singaraja RR, Zhou S, Silverston A, Huber MT, Moran J, James ER, Janoo R, Savill JM, Rigot V, Zhang L-H, Wang M, Chimini G, Wellington CL, Tafuri SR, Hayden MR: Protein kinase A site-specific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux. J Biol Chem 277: 41835–41842, 2002.

97.Wang Y, Oram JF: Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem 277: 5692–5697, 2002.

98.Wang Y, Kurdi-Haidar B, Oram JF: LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res 45: 972–980, 2004.

99.Feng B, Tabas I: ABCA1-mediated cholesterol efflux is defective in free choles- terol-loaded macrophages. J Biol Chem 277: 43271–43280, 2002.

100.Choi HY, Karten B, Chan T, Vance JE, Greer WL, Heidenreich RA, Garver WS, Francis GA: Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann–Pick type C disease. J Biol Chem 278: 32569–32577, 2003.

101.Albrecht C, Soumian S, Amey JS, Sardini A, Higgins CF, Davies AH, Gibbs RG: ABCA1 expression in carotid atherosclerotic plaques. Stroke 35: 2801–2806, 2004.

102.McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, Hoppe KL, Roach ML, Royer LJ, de Wet J, Broccardo C, Chimini G, Francone OL: High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA 97: 4245–4250, 2000.

114 Kathryn E. Naus and Cheryl L. Wellington

103.Christiansen-Weber TA, Voland JR, Wu Y, Ngo K, Roland BL, Nguyen S, Peterson PA, Fung-Leung WP: Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomeru-

lonephritis as well as high-density lipoprotein cholesterol deficiency. Am J Pathol 157: 1017–1029, 2000.

104.Orsó E, Broccardo C, Kaminski WE, Böttcher A, Liebisch G, Drobnik W, Götz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani M-F, Rothe G, Lackner KJ, Chimini G, Schmitz G: Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and ABC1-deficient mice. Nat Genet 24: 192–196, 2000.

105.Remaley AT, Stonick JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarinao-Fojo S, Brewer HB: Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun 280: 818–823, 2001.

106.Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF: Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clerning cellular cholesterol. J Clin Invest 94: 1698–1705, 1994.

107.Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, Segrest JP, Phillips MC, Rothblat GH: Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 34: 7955–7965, 1995.

108.Remaley AT, Thomas F, Stonick JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, Santamarina-Fojo S, Brewer HB: Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 44: 828–836, 2003.

109.Wang N, Silver DL, Costet P, Tall AR: Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1 [In Process Citation]. J Biol Chem 275: 33053–33058, 2000.

110.Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman MW: Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 277: 33178–33187, 2002.

111.Natarajan P, Forte TM, Chu B, Phillips MC, Oram JF, Bielicki JK: Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1. J Biol Chem 279: 24044–24052, 2004.

112.Oram JF, Lawn RM, Garvin MR, Wade DP: ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 275: 34508–34511, 2000.

113.Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J: Characterization of oligomeric human ATP binding cassette transporter A1: Potential implications for determining the structure of nascent high density lipoprotein particles. J Biol Chem 279: 41529–41536, 2004.

114.Wellington CL, Yang Y-Z, Zhou S, Clee SM, Tan B, Hirano K, Zwarts K, Kwok A, Gelfer A, Marcil M, Newman S, Roomp K, Singaraja R, Collins J, Zhang LH, Groen AK, Hovingh K, Brownlie A, Tafuri S, Genest J Jr, Kastelein JJ, Hayden MR: Truncation mutations in ABCA1 suppress normal upregulation of full-

length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. J Lipid Res 43: 1939–1949, 2002.

115.Chambenoit O, Hamon Y, Marguet D, Rigneault H, Rosseneu N, Chimini G: Specific docking of apolipoprotein A-1 at the cell surface requires a functional ABCA1 transporter. J Biol Chem, 276: 9955–9960, 2001.

116.Vaughan AM, Oram JF: ABCA1 redistributes membrane cholesterol independently of apolipoprotein interactions. J Lipid Res 44: 1373–1380, 2003.

117.Panagotopulos SE, Witting SR, Horace EM, Hui DY, Maiorano JN, Davidson WS: The role of apolipoprotein A-I helix 10 in apolipoprotein-mediated cholesterol efflux via the ATP-binding cassette transporter ABCA1. J Biol Chem 277: 39477–39484, 2002.

118.Gillotte KL, Zaiou M, Lund-Katz S, Anantharamaiah GM, Holvoet P, Dhoest A, Palgunachari MN, Segrest JP, Weisgraber KH, Rothblat GH, Phillips MC: Apolipoprotein-mediated plasma membrane microsolubilization: role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem 274: 2021–2028, 1999.

119.Gillotte KL, Davidson WS, Lund-Katz S, Rothblat GH, Phillips MC: Removal of cellular cholesterol by pre-β-HDL involves plasma membrane microsolubilization. J Lipid Res 39: 1918–1928, 1998.

120.Neufeld EB, Remaley AT, Demosky SJ, Stonik JA, Cooney AM, Comly M, Dwyer NK, Zhang M, Blanchette-Mackie JE, Santamarina-Fojo S, Brewer HB Jr: Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem 276: 27584–27590, 2001.

121.Rothblat GH, de la Llera-Moya M, Favari E, Yancey PG, Kellner-Weibel G: Cellular cholesterol flux studies: methodological considerations. Atherosclerosis 163: 1–8, 2002.

122.Wang N, Silver DL, Theile C, Tall AR: ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 276: 23742–23747, 2001.

123.Yamauchi Y, Abe-Dohmae S, Yokoyama S: Differential regulation of apolipoprotein A-I/ATP binding cassette transporter A1-mediated cholesterol and phospholipid release. Biochim Biophys Acta 1585: 1–10, 2002.

124.Fielding PE, Nagao K, Hakamata H, Chimini G, Fielding CJ: A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipoprotein A-I. Biochemistry 39: 14113–14120, 2000.

125.Chen W, Sun Y, Welch C, Gorelik A, Leventhal AR, Tabas I, Tall AR: Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes. J Biol Chem 276: 43564–43569, 2001.

126.Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, Yang Y-Z, Zhang LH, James E, Wilson JE, Francone O, McManus BM, Hayden MR: ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 82: 273–283, 2002.

127.Lawn RM, Wade DP, Couse TL, Wilcox JN: Localization of human ATP-bind- ing cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol 21: 378–385, 2001.

128.Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS: Targeted inactivation of hepatic Abca1 causes profound hypoalphalipopro-

116 Kathryn E. Naus and Cheryl L. Wellington

teinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115: 1333–1342, 2005.

129.Wellington CL, Brunham LR, Zhou S, Singaraja R, Visscher H, Gelfer A, Ross C, James E, Liu G, Huber MT, Yang YZ, Parks RJ, Groen A, Fruchart-Najib J, Hayden MR: Alterations in plasma lipids in mice via adenoviral mediated hepatic overexpression of human ABCA1. J Lipid Res 44: 1470–1480, 2003.

130.Basso F, Freeman L, Knapper CL, Remaley A, Stonik J, Neufeld EB, Tansey T, Amar MJA, Fruchart-Najib J, Duverger N, Santamarina-Fojo S, Brewer HB Jr: Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL-cholesterol concentrations. J Lipid Res 44: 296–302, 2003.

131.Hoekstra M, Kruijt JK, Van Eck M, van Berkel TJC: Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem 278: 25448–25453, 2003.

132.Kiss RS, McManus DC, Franklin V, Tan WL, McKenzie A, Chimini G, Marcel YL: The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways. J Biol Chem 278: 10119–10127, 2003.

133.Borst P, Zelcer N, van Helvoort A: ABC transporters in lipid transport. Biochim Biophys Acta 1486: 128–144, 2000.

134.Chen H, Rossier MD, Lalioti A, Lynn A, Charkravarti A, Perrin G, Antonarakis SE: Cloning of the cDNA for a human homologue of the Drosophila white gene and mapping to chromosome 21q22.3. Am J Hum Genet 59: 66–75, 1996.

135.Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, Shimizu N, Edwards PA: Characterization of the human ABCG1 gene. J Biol Chem 276: 39438–39447, 2001.

136.Lorkowski S, Rust S, Engel T, Jung E, Tegelkamp K, Galinski EA, Assmann G, Cullen P: Genomic sequence and structure of the human ABCG1 (ABC8) gene. Biochem Biophys Res Commun 280: 121–131, 2001.

137.Wang N, Lan D, Chen W, Matsuura F, Tall AR: ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101: 9774–9779, 2004.

138.Cserepes J, Szentpetery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, Glavinas H, Klein I, Homolya L, Varadi A, Sarkadi B, Elkind NB: Functional expression and characterization of the human ABCG1 and ABCG1 proteins: indications for heterodimerization. Biochem Biophys Res Commun 320: 860–867, 2004.

139.Langmann T, Porsch-Özcürümez M, Unkelbach U, Klucken J, Schmitz G: Genomic organization and characterization of the promoter of the human ATPbinding cassette transporter-G1 (ABCG1) gene. Biochim Biophys Acta 1494: 175–180, 2000.

140.Nakamura K, Kennedy MA, Baldán A, Bohanic DD, Lyons K, Edwards PA: Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J Biol Chem August 19 Epub: 2004.

141.Croop JM, Tiller GE, Fletcher JA, Lux E, Raab D, Goldenson D, Son S, Arciniegas S, Wu RL: Isolation and characterization of a mammalian homolog of the Drosophila white gene. Gene 185: 77–85, 1997.

142.Kennedy MA, Barrera GC, Nakamura K, Baldán A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA: ABCG1 has a critical role in mediating cholesterol efflux to HDl and preventing cellular lipid accumulation. Cell Metabol 1: 121–131, 2005.

143.Klucken J, Büchler C, Orsó E, Kaminski WE, Porsch-Özcürümez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G: ABCG1 (ABC8), the human homologue of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 97: 817–822, 2000.

144.Venkateswaran AJ, Repa JJ, Lobaraccaro JM, Bronson A, Magnelsorf DJ, Edwards PA: Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 275: 14700–14707, 2000.

145.Lorkowski S, Kratz M, Wenner C, Schmidt R, Weitkamp B, Fobker M, Reinhardt J, Rauterberg J, Galinski EA, Cullen P: Expression of the ATP-bind- ing cassette transporter gene ABCG1 (ABC8) in Tangier disease. Biochem Biophys Res Commun 283: 821–830, 2001.

146.Cignarella A, Engel T, von Eckardstein A, Kratz M, Lorkowski S, Lueken A, Assmann G, Cullen P: Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. Atheroscler 179: 229–236, 2005.

147.Fazio S, Linton MF: Murine bone marrow transplantation as a novel approach to studying the role of macrophages in lipoprotein metabolism and atherogenesis. Trends Cardiovasc Med 6: 58–65, 1996.

148.Small JA, Bieberich C, Ghotbi Z, Hess J, Scangos GA, Clements JE: The visna virus long terminal repeat directs expression of a reporter gene in activated macrophages, lymphocytes, and the central nervous systems of transgenic mice. J Virol 63: 1891–1896, 1989.

149.Daugherty A: Mouse models of atherosclerosis. Am J Med Sci 323: 3–10, 2002.

150.Smith JD, Breslow JL: The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med 242: 99–109, 1997.

151.Tangirala RK, Rubin EM, Palinski W: Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptordeficient and apolipoprotein E-deficient mice. J Lipid Res 36: 2320–2328, 1995.

152.Mahley RW, Rall SC Jr: Apolipoprotein E: far more than a lipid transport protein. Ann Rev Genom Hum Genet 1: 507–537, 2000.

153.Greenow K, Pearce NJ, Ramji DP: The key role of apolipoprotein E in atherosclerosis. J Mol Med 83: 329–342, 2005.

154.Mazzone T: Apolipoprotein E secretion by macrophages: its potential functions. Curr Opin Lipidol 7: 303–310, 1996.

155.von Eckardstein A: Cholesterol efflux from macrophages and other cells. Curr Opin Lipidol 7: 308–319, 1996.

156.Langer C, Huang Y, Cullen P, Mahley RW, Assmann G, von Eckardstein A: Endogenous apolipoprotein E modulates cholesterol efflux and cholesterol

ester hydrolysis mediated by high density lipoprotein3 and lipid-free apolipoproteins in mouse peritoneal macrophages. J Mol Med 77: 614–622, 2000.

157.Basu SK, Ho YK, Brown MS, Bilheimer DW, Anderson RGW, Goldstein JL: Biochemical and genetic studies of the apolipoprotein E secreted by mouse macrophages and human monocytes. J Biol Chem 257: 9788–9795, 1982.

158.Basu SK, Goldstein JL, Brown ML: Independent pathways for secretion of cholesterol and apolipoprotein E by macrophages. Science 219: 871–873, 1983.